Navigation Links
Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
Date:12/6/2010

investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Forward Looking Statements

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events. There can be no assurance that that the data presented during the 2010 International Scientific Conference of the World Allergy Association (WAO) regarding Cinryze is predictive of how Cinryze will perform in commercial usage.  Cinryze is currently available only in the United States.  Cinryze is not approved in the U.S. for acute treatment of attacks nor has the safety and effectiveness of Cinryze been established in pediatric patients with HAE. We cannot assure that current or future studies with Cinryze in the patient populations described in the WAO presentations may demonstrate the safety and efficacy profile of Cinryze. The EMA may view the data regarding the use of Cinryze for acute treatment and / or prevention of HAE we have submitted in the MAA as insufficient or inconclusive, request additional data, require additional clinical studies, delay any decision past the time frames anticipated by us, limit any approved indications, deny the approval of Cinryze for acute treatment and / or prevention of HAE or approve a competing product which has been granted orphan drug designation thereby preventing Cinryze from reaching the European market.  For example, in June 2009, the U.S. FDA issued a complete response letter and requested an additional clinical study, due to their opinion that the placebo controlled study submitted in support of the sBLA for acute treatment of HAE lacked robustness. These factors, and other factors, including, but not limited
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
2. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
3. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
4. Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
5. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
6. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
7. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
8. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
9. Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
10. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
11. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 According to ... by Product (Consumables, Instruments, Services), by Test Type (Indirect, ... Flow Cytometry), by End Users - Global Forecast to ... is expected to reach $736.85 Million by 2020 from ... 10.25%. Browse 71 market data Tables ...
(Date:5/22/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/28m7nx/guide_to_prepare ) has announced ... Application Dossiers for Oversea Medical device registration and ... to their offering. The Chinese medical ... the most growth potentiality, which is attracting more ... to penetrate such market. It is estimated that ...
(Date:5/22/2015)... InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), ... that its CGuard TM Embolic Prevention System reported positive ... Musialek , at the EuroPCR conference on May ... PARADIGM, an investigator-initiated P rospective evaluation of ... revascularization I n symptomatic and increased-risk asymptomatic carotid artery ...
Breaking Medicine Technology:Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4
(Date:5/22/2015)... Gateway Building Concepts is experienced with ... the company specialize in include decks, additions, kitchen remodeling, ... and much more. , The redesigned logo is ... the company. It includes two geometrical lines that represent ... out to be used with many things associated with ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Medivo, Inc., a ... “Positivity Rates and Genotype Results in ‘Baby Boomers’ Screened for ... a Nationwide Lab Test Database” at Digestive Disease Week, May ... Clinical Affairs and Analytics team members Carol Smyth, MB; Jason ... Andrea Parker, MSI, along with Nancy Reau, MD from the ...
(Date:5/22/2015)... sweetFrog Enterprises, LLC. is pleased to announce the opening ... the 16th sweetFrog store located in the Lone Star State. ... the Inc. 500 list of fastest growing companies in 2014. ... Texas for 20 years and love the natural beauty and ... nearby Palestine, sweetFrog locations. “We are really excited about giving ...
(Date:5/22/2015)... Alexandria, VA (PRWEB) May 22, 2015 ... be presented at the American Society of Clinical ... May, demonstrated improved survival rates for those patients ... standard chemotherapy regimen of pemetrexed/cisplatin. Bevacizumab (Avastin® Genentech, ... vessel growth), and it is already routinely used ...
(Date:5/22/2015)... Wimbledon Health Partners, the leading on-site ... and NCV testing , is proud to announce ... American National athlete, to the Wimbledon Athletics division. ... level of testing and information it provides to be ... trainers, this way they can focus on the task ...
Breaking Medicine News(10 mins):Health News:Medivo Study Finds HCV Positivity Rates are 250% Higher Among Baby Boomers 2Health News:sweetFrog Opens New Location in Jacksonville, Texas 2Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2Health News:Wimbledon Athletics Recruits Team USA Athlete 2Health News:Wimbledon Athletics Recruits Team USA Athlete 3
... school building will be reopened after a medical report found no ... staffs working on the 16th and 17th floors of the building. ... cluster was detected in the staffs working in the top two ... found to have malignant tumors, while six had benign tumors. ...
... new cases of skin cancer will be diagnosed in ... deadly //condition is extremely treatable, averaging a cure rate ... involve treating or removing both cancerous and healthy skin, ... the cancerous cells. ,Speaking today at ACADEMY ’06, ...
... things on her hormones: unpredictable emotions, weight gain and ... , These changes occur as the levels of hormones ... abnormalities in hormone levels occur. A dermatologist can provide ... during a woman’s lifetime. ,Speaking today at ACADEMY ...
... for a while due to its eradication, yet people could ... not been vaccinated says a recent report.// ... had spread after an unvaccinated teenager contracted the virus and ... gathering. This spurred a large outbreak in USA, which also ...
... CMV infects about 40,000 children before birth and about ... the virus – almost one an hour.// , ... disability, a lack of coordination, and seizures. According to ... as common a cause of serious disability as Down ...
... held every two years in various cities around the world, ... of August. // ,The conference, ‘AIDS 2006’, which is ... 20,000 participants from across 120 countries. This conference, whose theme ... for the world’s top medical authorities and AIDS experts, will ...
Cached Medicine News:Health News:Emerging Therapies for Skin Cancer Treatment 2Health News:Emerging Therapies for Skin Cancer Treatment 3Health News:Emerging Therapies for Skin Cancer Treatment 4Health News:A Balancing Act: Hormones and the Skin 2Health News:A Balancing Act: Hormones and the Skin 3Health News:A Balancing Act: Hormones and the Skin 4Health News:Creation of Cytomegalovirus Vaccine by an Innovative Method 2Health News:XVI International AIDS Conference To Be Held In Toronto In August 2
Bipolar forceps...
... in vitro Nucleic Acid Hybridization ... Microplate Chemiluminescence for the Qualitative ... Types 6,11,16,18,31,33,35,39,42,43,44,45,51,52,56,58,59 and 68 and ... High-Risk Groups in Cervical Specimens: ...
... superb radiation protection-0.62mm (+/- .05)Pb lead glass ... to their level of protection, they are ... smoothly on your bridge while hugging your ... wear corrective lenses, you can order Leaded ...
... first time in the world, there is a ... to diagnose VVC in female patients. CanDia5® is ... detect the Candida antigens almost instantaneously (within 5 ... blood. There is no similar POC product for ...
Medicine Products: